Inhibitors of aldo-keto reductases AKR1C1-AKR1C4

Current Medicinal Chemistry

Volumn 18, Issue 17, 2011, Pages 2554-2565

  Brozic P ^a   Turk, S ^a   Rižner, T Lanišnik ^a   Gobec, S ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Aldo keto reductases; Cancer; Drug discovery; Enzyme inhibitors; Flavonoids; Non steroidal anti inflammatory drugs; Steroids

Indexed keywords

2' HYDROXYFLAVONE; 7 HYDROXYFLAVONE; ALDEHYDE REDUCTASE; ALDO KETO REDUCTASE 1C1; ALDO KETO REDUCTASE 1C2; ALDO KETO REDUCTASE 1C3; ALDO KETO REDUCTASE 1C4; ALDOSE REDUCTASE INHIBITOR; ANDROGEN RECEPTOR; BENZODIAZEPINE DERIVATIVE; BIOCHANIN A; CINNAMIC ACID DERIVATIVE; COUMESTROL; CYCLOPENTANE DERIVATIVE; ESTROGEN RECEPTOR; FLAVONOID; GLYCYRRHETINIC ACID; ISOENZYME; JASMONIC ACID; JASMONIC ACID METHYL ESTER; NARINGENIN; NEUROSTEROID; NONSTEROID ANTIINFLAMMATORY AGENT; PROGESTERONE RECEPTOR; PROSTAGLANDIN DERIVATIVE; QUERCETIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; XENOBIOTIC AGENT; ZEARALENONE;

ARTICLE; BREAST CANCER; CATAMENIAL EPILEPSY; DEPRESSION; DRUG DESIGN; DRUG SCREENING; DRUG TARGETING; ENDOMETRIOSIS; ENDOMETRIUM CANCER; ENZYME ACTIVE SITE; ENZYME INHIBITION; HUMAN; PREMENSTRUAL SYNDROME; PROSTATE CANCER; RECEPTOR OCCUPANCY; STRUCTURE ACTIVITY RELATION; TRANSACTIVATION; XENOBIOTIC METABOLISM;

20-HYDROXYSTEROID DEHYDROGENASES; AMINO ACID SEQUENCE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CATALYTIC DOMAIN; CINNAMATES; DRUG DESIGN; DRUG DISCOVERY; ENZYME INHIBITORS; FLAVONOIDS; GONADAL STEROID HORMONES; HUMANS; MODELS, MOLECULAR; NEUROTRANSMITTER AGENTS; PROTEIN STRUCTURE, SECONDARY; SALICYLATES; SEQUENCE ALIGNMENT;

EID: 79957965751     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711795933713     Document Type: Article

References (62)

1. Penning, T.M. Molecular endocrinology of hydroxysteroid dehydrogenases. Endocr. Rev., 1997, 18, 281-305. (Pubitemid 27246879)
2. Penning, T.M.; Drury, J.E. Human aldo-keto reductases: function, gene regulation, and single nucleotide polymorphisms. Arch. Biochem. Biophys., 2007, 464, 241-250. (Pubitemid 47214569)
3. Penning, T.M.; Byrns, M.C. Steroid hormone transforming aldo-keto reductases and cancer. Ann. N. Y. Acad. Sci., 2009, 1155, 33-42.
4. Penning, T.M.; Burczynski, M.E.; Jez, J.M.; Hung, C.F.; Lin, H.K.; Ma, H.; Moore, M.; Palackal, N.; Ratnam, K. Human 3alpha-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones. Biochem. J., 2000, 351, 67-77.
5. Hyndman, D.; Bauman, D.R.; Heredia, V.V.; Penning, T.M. The aldo-keto reductase superfamily homepage. Chem. Biol. Interact., 2003, 143-144, 621-631. (Pubitemid 36246464)
6. Lani-nik Ri ner, T.; muc, T.; Rupreht, R.; inkovec, J.; Penning, T.M. AKR1C1 and AKR1C3 may determine progesterone and estrogen ratios in endometrial cancer. Mol. Cell. Endocrinol., 2006, 248, 126-135.
7. Blouin, K.; Blanchette, S.; Richard, C.; Dupont, P.; Luu-The, V.; Tchernof, A. Expression and activity of steroid aldoketoreductases 1C in omental adipose tissue are positive correlates of adiposity in women. Am. J. Physiol. Endocrinol. Metab., 2005, 288, E398-404. (Pubitemid 40110649)
8. Sharma, K.K.; Lindqvist, A.; Zhou, X.J.; Auchus, R.J.; Penning, T.M.; Andersson, S. Deoxycorticosterone inactivation by AKR1C3 in human mineralocorticoid target tissues. Mol. Cell. Endocrinol., 2006, 248, 79-86.
9. Lani-nik Ri ner, T.; Lin, H.K.; Peehl, D.M.; Steckelbroeck, S.; Bauman, D.R.; Penning, T.M. Human type 3 3alpha-hydroxysteroid dehydrogenase (aldo-keto reductase 1C2) and androgen metabolism in prostate cells. Endocrinology, 2003, 144, 2922-2932.
10. Steckelbroeck, S.; Jin, Y.; Gopishetty, S.; Oyesanmi, B.; Penning, T.M. Human cytosolic 3alpha-hydroxysteroid dehydrogenases of the aldo-keto reductase superfamily display significant 3beta-hydroxysteroid dehydrogenase activity: implications for steroid hormone metabolism and action. J. Biol. Chem., 2004, 279, 10784-10795. (Pubitemid 38379543)
11. Nobel, S.; Abrahmsen, L.; Oppermann, U. Metabolic conversion as a prereceptor control mechanism for lipophilic hormones. Eur. J. Biochem., 2001, 268, 4113-4125. (Pubitemid 32862871)
12. Dufort, I.; Rheault, P.; Huang, X.F.; Soucy, P.; Luu-The, V. Characteristics of a highly labile human type 5 17beta-hydroxysteroid dehydrogenase. Endocrinology, 1999, 140, 568-574. (Pubitemid 29058186)
13. Dufort, I.; Labrie, F.; Luu-The, V. Human types 1 and 3 3-alphahydroxysteroid dehydrogenases: differential lability and tissue distribution. J. Clin. Endocrinol. Metab., 2001, 86, 841-846. (Pubitemid 32208285)
14. Penning, T.M.; Jin, Y.; Steckelbroeck, S.; Lani-nik Ri ner, T.; Lewis, M. Structure-function of human 3-alpha-hydroxysteroid dehydrogenases: genes and proteins. Mol. Cell. Endocrinol., 2004, 215, 63-72. (Pubitemid 38337424)
15. Henderson, B.E.; Feigelson, H.S. Hormonal carcinogenesis. Carcinogenesis, 2000, 21, 427-433. (Pubitemid 30137927)
16. muc, T.; Hevir, N.; Ribic-Pucelj, M.; Husen, B.; Thole, H.; Lani-nik Ri ner, T. Disturbed estrogen and progesterone action in ovarian endometriosis. Mol. Cell. Endocrinol., 2009, 301, 59-64.
17. Ji, Q.; Aoyama, C.; Nien, Y.; Liu, P.I.; Chen, P.K.; Chang, L.; Stanczyk, F.Z.; Stolz, A. Selective loss of AKR1C1 and AKR1C2 in breast cancer and their potential effect on progesterone signaling. Cancer Res., 2004, 64, 7610-7617. (Pubitemid 39372107)
18. Higaki, Y.; Usami, N.; Shintani, S.; Ishikura, S.; El-Kabbani, O.; Hara, A. Selective and potent inhibitors of human 20alpha-hydroxysteroid dehydrogenase (AKR1C1) that metabolizes neurosteroids derived from progesterone. Chem. Biol. Interact., 2003, 143-144, 503-513. (Pubitemid 36253599)
19. Usami, N.; Yamamoto, T.; Shintani, S.; Ishikura, S.; Higaki, Y.; Katagiri, Y.; Hara, A. Substrate specificity of human 3(20)alpha-hydroxysteroid dehydrogenase for neurosteroids and its inhibition by benzodiazepines. Biol. Pharm. Bull., 2002, 25, 441-445. (Pubitemid 40044660)
20. Wang, S.; Yang, Q.; Fung, K.; Lin, H. AKR1C2 and AKR1C3 mediated prostaglandin D2 metabolism augments the PI3K/Akt proliferative signaling pathway in human prostate cancer cells. Mol. Cell. Endocrinol., 2008, 289, 60-66.
21. Lovering, A.L.; Ride, J.P.; Bunce, C.M.; Desmond, J.C.; Cummings, S.M.; White, S.A. Crystal structures of prostaglandin D(2) 11-ketoreductase (AKR1C3) in complex with the nonsteroidal anti-inflammatory drugs flufenamic acid and indomethacin. Cancer Res., 2004, 64, 1802-1810. (Pubitemid 38428705)
22. Desmond, J.C.; Mountford, J.C.; Drayson, M.T.; Walker, E.A.; Hewison, M.; Ride, J.P.; Luong, Q.T.; Hayden, R.E.; Vanin, E.F.; Bunce, C.M. The aldoketo reductase AKR1C3 is a novel suppressor of cell differentiation that provides a plausible target for the non-cyclooxygenase-dependent antineoplastic actions of nonsteroidal anti-inflammatory drugs. Cancer Res., 2003, 63, 505-512. (Pubitemid 36152514)
23. Byrns, M.C.; Duan, L.; Lee, S.H.; Blair, I.A.; Penning, T.M. Aldo-keto reductase 1C3 expression in MCF-7 cells reveals roles in steroid hormone and prostaglandin metabolism that may explain its over-expression in breast cancer. J. Steroid Biochem. Mol. Biol., 2010, 118, 177-187.
24. Quinkler, M.; Bujalska, I.J.; Tomlinson, J.W.; Smith, D.M.; Stewart, P.M. Depot-specific prostaglandin synthesis in human adipose tissue: a novel possible mechanism of adipogenesis. Gene, 2006, 380, 137-143. (Pubitemid 44363149)
25. Jin, Y.; Duan, L.; Lee, S.H.; Kloosterboer, H.J.; Blair, I.A.; Penning, T.M. Human cytosolic hydroxysteroid dehydrogenases of the aldo-ketoreductase superfamily catalyze reduction of conjugated steroids: implications for phase I and phase II steroid hormone metabolism. J. Biol. Chem., 2009, 284, 10013-10022.
26. Steckelbroeck, S.; Oyesanmi, B.; Jin, Y.; Lee, S.; Kloosterboer, H.J.; Penning, T.M. Tibolone metabolism in human liver is catalyzed by 3alpha/3beta-hydroxysteroid dehydrogenase activities of the four isoforms ofthe aldo-keto reductase (AKR)1C subfamily. J. Pharmacol. Exp. Ther., 2006, 316, 1300-1309. (Pubitemid 43345306)
27. Hung, J.; Chow, K.; Wang, H.; Wang, L. Expression of dihydrodiol dehydrogenase and resistance to chemotherapy and radiotherapy in adenocarcinoma cells of lung. Anticancer Res., 2006, 26, 2949-2955. (Pubitemid 44161785)
28. Jez, J.M.; Bennett, M.J.; Schlegel, B.P.; Lewis, M.; Penning, T.M. Comparative anatomy of the aldo-keto reductase superfamily. Biochem. J., 1997, 326 (3), 625-636. (Pubitemid 27438032)
29. The PyMOL Molecular Graphics System, Version 1.3, Schrödinger, LLC.
30. Qiu, W.; Zhou, M.; Labrie, F.; Lin, S. Crystal structures of the multispecific 17beta-hydroxysteroid dehydrogenase type 5: critical androgen regulation in human peripheral tissues. Mol. Endocrinol., 2004, 18, 1798-1807. (Pubitemid 38859585)
31. Jin, Y.; Stayrook, S.E.; Albert, R.H.; Palackal, N.T.; Penning, T.M.; Lewis, M. Crystal structure of human type III 3alpha-hydroxysteroid dehydrogenase/bile acid binding protein complexed with NADP(+) and ursodeoxycholate. Biochemistry, 2001, 40, 10161-10168. (Pubitemid 32800122)
32. Couture, J.; Legrand, P.; Cantin, L.; Luu-The, V.; Labrie, F.; Breton, R. Human 20alpha-hydroxysteroid dehydrogenase: crystallographic and sitedirected mutagenesis studies lead to the identification of an alternative binding site for C21-steroids. J. Mol. Biol., 2003, 331, 593-604. (Pubitemid 36937148)
33. Schlegel, B.P.; Jez, J.M.; Penning, T.M. Mutagenesis of 3 alphahydroxysteroid dehydrogenase reveals a "push-pull" mechanism for proton transfer in aldo-keto reductases. Biochemistry, 1998, 37, 3538-3548. (Pubitemid 28125582)
34. Deluca, D.; Möller, G.; Rosinus, A.; Elger, W.; Hillisch, A.; Adamski, J. Inhibitory effects of fluorine-substituted estrogens on the activity of 17betahydroxysteroid dehydrogenases. Mol. Cell. Endocrinol., 2006, 248, 218-224.
35. Penning, T.M.; Burczynski, M.E.; Jez, J.M.; Lin, H.K.; Ma, H.; Moore, M.; Ratnam, K.; Palackal, N. Structure-function aspects and inhibitor design of type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3). Mol. Cell. Endocrinol., 2001, 171, 137-149. (Pubitemid 32098208)
36. Qiu, W.; Zhou, M.; Mazumdar, M.; Azzi, A.; Ghanmi, D.; Luu-The, V.; Labrie, F.; Lin, S. Structure-based inhibitor design for an enzyme that binds different steroids: a potent inhibitor for human type 5 17beta-hydroxysteroid dehydrogenase. J. Biol. Chem., 2007, 282, 8368-8379. (Pubitemid 47093565)
37. Bydal, P.; Luu-The, V.; Labrie, F.; Poirier, D. Steroidal lactones as inhibitors of 17beta-hydroxysteroid dehydrogenase type 5: chemical synthesis, enzyme inhibitory activity, and assessment of estrogenic and androgenic activities. Eur J Med Chem, 2009, 44, 632-644.
38. Bauman, D.R.; Rudnick, S.I.; Szewczuk, L.M.; Jin, Y.; Gopishetty, S.; Penning, T.M. Development of nonsteroidal anti-inflammatory drug analogs and steroid carboxylates selective for human aldo-keto reductase isoforms: potential antineoplastic agents that work independently of cyclooxygenase isozymes. Mol. Pharmacol., 2005, 67, 60-68. (Pubitemid 40069966)
39. Krazeisen, A.; Breitling, R.; Möller, G.; Adamski, J. Phytoestrogens inhibit human 17beta-hydroxysteroid dehydrogenase type 5. Mol. Cell. Endocrinol., 2001, 171, 151-162. (Pubitemid 32098209)
40. Broi, P.; Gobec, S.; Laninik Ri ner; T. In: Enzymology and Molecular Biology of Carbonyl Metabolism 13, Weiner, H.; Maser, E.; Lindahl, R.; Plapp, B., Eds.; Purdue University: Purdue, 2007; pp. 252-262..
41. Broi, P.; muc, T.; Gobec, S.; Laninik Ri ner, T. Phytoestrogens as inhibitors of the human progesterone metabolizing enzyme AKR1C1. Mol. Cell. Endocrinol., 2006, 259, 30-42. (Pubitemid 44419585)
42. Skarydová, L.; Zivná, L.; Xiong, G.; Maser, E.; Wsól, V. AKR1C3 as a potential target for the inhibitory effect of dietary flavonoids. Chem. Biol. Interact., 2009, 178, 138-144.
43. Winkel-Shirley, B. Flavonoid biosynthesis. A colorful model for genetics, biochemistry, cell biology, and biotechnology. Plant Physiol., 2001, 126, 485-493. (Pubitemid 32566604)
44. Treutter, D. Significance of flavonoids in plant resistance and enhancement of their biosynthesis. Plant Biol (Stuttg), 2005, 7, 581-591. (Pubitemid 43004025)
45. Miyahisa, I.; Funa, N.; Ohnishi, Y.; Martens, S.; Moriguchi, T.; Horinouchi, S. Combinatorial biosynthesis of flavones and flavonols in Escherichia coli. Appl. Microbiol. Biotechnol., 2006, 71, 53-58.
46. Broi, P.; Golob, B.; Gomboc, N.; Laninik Riner, T.; Gobec, S. Cinnamic acids as new inhibitors of 17beta-hydroxysteroid dehydrogenase type 5 (AKR1C3). Mol. Cell. Endocrinol., 2006, 248, 233-235.
47. Liu, L.; Hudgins, W.R.; Shack, S.; Yin, M.Q.; Samid, D. Cinnamic acid: a natural product with potential use in cancer intervention. Int. J. Cancer, 1995, 62, 345-350.
48. Davies, N.J.; Hayden, R.E.; Simpson, P.J.; Birtwistle, J.; Mayer, K.; Ride, J.P.; Bunce, C.M. AKR1C isoforms represent a novel cellular target for jasmonates alongside their mitochondrial-mediated effects. Cancer Res., 2009, 69, 4769-4775.
49. tefane, B.; Broi, P.; Vehovc, M.; Laninik Ri ner, T.; Gobec, S. New cyclopentane derivatives as inhibitors of steroid metabolizing enzymes AKR1C1 and AKR1C3. Eur J Med Chem, 2009, 44, 2563-2571.
50. Penning, T.M.; Talalay, P. Inhibition of a major NAD(P)-linked oxidoreductase from rat liver cytosol by steroidal and nonsteroidal antiinflammatory agents and by prostaglandins. Proc. Natl. Acad. Sci. U.S.A., 1983, 80, 4504-4508. (Pubitemid 13077867)
51. Sokoloski, J.A.; Sartorelli, A.C. Induction of the differentiation of HL-60 promyelocytic leukemia cells by nonsteroidal anti-inflammatory agents in combination with low levels of vitamin D3. Leuk. Res., 1998, 22, 153-161. (Pubitemid 28185346)
52. Nagase, T.; Miyajima, N.; Tanaka, A.; Sazuka, T.; Seki, N.; Sato, S.; Tabata, S.; Ishikawa, K.; Kawarabayasi, Y.; Kotani, H.; et al. Prediction of the coding sequences of unidentified human genes. III. The coding sequences of 40 new genes (KIAA0081-KIAA0120) deduced by analysis of cDNA clones from human cell line KG-1. DNA Res., 1995, 2, 37-43.
53. Kalgutkar, A.S.; Crews, B.C.; Saleh, S.; Prudhomme, D.; Marnett, L.J. Indolyl esters and amides related to indomethacin are selective COX-2 inhibitors. Bioorg. Med. Chem., 2005, 13, 6810-6822. (Pubitemid 41571227)
54. Byrns, M.C.; Penning, T.M. Type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs. Chem. Biol. Interact., 2009, 178, 221-227.
55. Byrns, M.C.; Steckelbroeck, S.; Penning, T.M. An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3alpha-HSD, type 5 17beta-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignancies. Biochem. Pharmacol., 2008, 75, 484-493. (Pubitemid 350298472)
56. Dhagat, U.; Carbone, V.; Chung, R.P.; Matsunaga, T.; Endo, S.; Hara, A.; El-Kabbani, O. A salicylic acid-based analogue discovered from virtual screening as a potent inhibitor of human 20alpha-hydroxysteroid dehydrogenase. Med Chem, 2007, 3, 546-550. (Pubitemid 350303069)
57. Gobec, S.; Broi, P.; Laninik Ri ner, T. Nonsteroidal anti-inflammatory drugs and their analogues as inhibitors of aldo-keto reductase AKR1C3: new lead compounds for the development of anticancer agents. Bioorg. Med. Chem. Lett., 2005, 15, 5170-5175. (Pubitemid 41463641)
58. Mills, K.I.; Gilkes, A.F.; Sweeney, M.; Choudhry, M.A.; Woodgate, L.J.; Bunce, C.M.; Brown, G.; Burnett, A.K. Identification of a retinoic acid responsive aldoketoreductase expressed in HL60 leukaemic cells. FEBS Lett., 1998, 440, 158-162. (Pubitemid 28558756)
59. Bro ic, P.; Cesar, J.; Kova, A.; Davies, M.; Johnson, A.P.; Fishwick, C.W.G.; Laninik Ri ner, T.; Gobec, S. Derivatives of pyrimidine, phthalimide and anthranilic acid as inhibitors of human hydroxysteroid dehydrogenase AKR1C1. Chem. Biol. Interact., 2009, 178, 158-164.
60. Dhagat, U.; Endo, S.; Sumii, R.; Hara, A.; El-Kabbani, O. Selectivity determinants of inhibitor binding to human 20alpha-hydroxysteroid dehydrogenase: crystal structure of the enzyme in ternary complex with coenzyme and the potent inhibitor 3,5-dichlorosalicylic acid. J. Med. Chem., 2008, 51, 4844-4848.
61. Broi, P.; Turk, S.; Laninik Riner, T.; Gobec, S. Discovery of new inhibitors of aldo-keto reductase 1C1 by structure-based virtual screening. Mol. Cell. Endocrinol., 2009, 301, 245-250.
62. El-Kabbani, O.; Scammells, P.J.; Gosling, J.; Dhagat, U.; Endo, S.; Matsunaga, T.; Soda, M.; Hara, A. Structure-guided design, synthesis, and evaluation of salicylic acid-based inhibitors targeting a selectivity pocket in the active site of human 20alpha-hydroxysteroid dehydrogenase (AKR1C1). J. Med. Chem., 2009, 52, 3259-3264.